| Texto completo | |
| Autor(es): |
Terra, M. F.
;
Garcia-Arevalo, M.
;
Avelino, T. M.
;
Degaki, K. Y.
;
Malospirito, C. C.
;
de Carvalho, M.
;
Torres, F. R.
;
Saito, A.
;
Figueira, A. C. M.
Número total de Autores: 9
|
| Tipo de documento: | Artigo Científico |
| Fonte: | METABOLISM OPEN; v. 17, p. 9-pg., 2023-03-01. |
| Resumo | |
Obesity is one of the main risk factors for type 2 diabetes, and peroxisome proliferator-activated receptor gamma (PPAR gamma) is considered a promising pathway on insulin sensitivity and adipose tissue metabolism. The search for molecules acting as insulin sensitizers have increased, especially for molecules that block PPAR gamma-Ser273 phosphorylation, without reaching full agonism. We evaluated the in vivo effects of AM-879, a PPAR gamma non-agonist, and found that AM-879 exerts different effects in mice depending on the dose. At lower doses, this ligand decreased BAT, increased leptin and Crh expression. However, at a higher dose, it promoted improvement on insulin sensitivity, ameliorates expression of metabolism-related genes, decreased the expression of genes related to liver toxicity, maintaining body weight and adipocyte size. These results present a new lead molecule to ameliorates insulin resistance and confirm AM-879 as a PPAR gamma non-agonist which blocks Ser273 phosphorylation as a good strategy to modulate insulin sensitivity without developing the adverse effects promoted by PPAR gamma full agonists. (AU) | |
| Processo FAPESP: | 16/22246-0 - Mecanismos de repressão do PPAR gama como alvo para combate ao diabetes e obesidade. |
| Beneficiário: | Ana Carolina Migliorini Figueira |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |